Spyre says SPY003 shows statistically significant RHI reduction at Week 12
Spyre’s SPY003 (anti-IL-23) met its primary endpoint with a statistically significant 10.0-point reduction in Robart’s Histopathology Index score versus baseline at Week 12 (p<0.0001).